Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
7.27
+0.68 (10.32%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Capricor Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | 22.27 | 25.18 | 2.55 | 0.24 | |
Revenue Growth | - | - | -11.55% | 886.81% | 941.85% | -21.06% |
Cost of Revenue | 99.73 | 84.45 | 49.97 | 36.45 | 21.82 | 13.57 |
Gross Profit | -99.73 | -84.45 | -27.7 | -11.27 | -19.27 | -13.33 |
Selling, General & Admin | 35.43 | 23.69 | 14.87 | 12.81 | 10.43 | 7.61 |
Operating Expenses | 35.43 | 23.69 | 14.87 | 12.81 | 10.43 | 7.61 |
Operating Income | -135.16 | -108.14 | -42.56 | -24.08 | -29.7 | -20.94 |
Interest Expense | -3.05 | -3.05 | - | - | - | - |
Interest & Investment Income | 8.85 | 6.26 | 2.2 | 1.73 | 0.52 | 0.06 |
Other Non Operating Income (Expenses) | 0.1 | 0.05 | 0.01 | 0.07 | - | - |
EBT Excluding Unusual Items | -129.26 | -104.88 | -40.35 | -22.28 | -29.18 | -20.88 |
Gain (Loss) on Sale of Assets | -0.16 | -0.16 | -0.11 | -0.01 | -0.03 | -0.01 |
Other Unusual Items | - | - | - | - | 0.19 | 0.87 |
Pretax Income | -129.41 | -105.04 | -40.47 | -22.29 | -29.02 | -20.02 |
Income Tax Expense | 0 | 0 | 0 | - | - | - |
Net Income | -129.42 | -105.04 | -40.47 | -22.29 | -29.02 | -20.02 |
Net Income to Common | -129.42 | -105.04 | -40.47 | -22.29 | -29.02 | -20.02 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 52 | 46 | 35 | 27 | 25 | 23 |
Shares Outstanding (Diluted) | 52 | 46 | 35 | 27 | 25 | 23 |
Shares Change | 24.20% | 31.97% | 31.52% | 9.06% | 6.34% | 48.28% |
EPS (Basic) | -2.47 | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 |
EPS (Diluted) | -2.47 | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -129.78 | -81.54 | -41.53 | -27.64 | 1.56 | -18.01 |
Free Cash Flow Per Share | -2.47 | -1.75 | -1.18 | -1.03 | 0.06 | -0.78 |
Gross Margin | - | - | -124.37% | -44.76% | - | - |
Operating Margin | - | - | -191.12% | -95.63% | -1163.93% | -8549.86% |
Profit Margin | - | - | -181.71% | -88.52% | -1137.37% | -8175.86% |
Free Cash Flow Margin | - | - | -186.50% | -109.79% | 61.02% | -7352.29% |
EBITDA | -133.07 | -106.25 | -41.14 | -23.01 | -29.16 | -20.69 |
EBITDA Margin | - | - | -184.72% | -91.39% | - | - |
D&A For EBITDA | 2.09 | 1.89 | 1.43 | 1.07 | 0.53 | 0.25 |
EBIT | -135.16 | -108.14 | -42.56 | -24.08 | -29.7 | -20.94 |
EBIT Margin | - | - | -191.12% | -95.63% | - | - |
Revenue as Reported | - | - | 22.27 | 25.18 | 2.55 | 0.24 |